http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 14 Jul 2026 08:04:46 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Humacyte+adds+two+nephrologists+as+advisors+for+dialysis+product+push/26765193.html <p>Humacyte, Inc. (Nasdaq: HUMA) announced the appointment of two nephrologists as advisors to support the planned commercialization of its acellular tissue engineered vessel (ATEV) in hemodialysis access, according to a company statement.</p><p>Robert J. Kossmann, MD, and Prabir Roy-Chaudhury, MD, PhD, will contribute to health economic, reimbursement, and market access strategies, as well as peer-to-peer scientific support and medical education.</p><p>Dr. Kossmann held senior medical leadership roles at Fresenius Medical Care from 2014 to 2026, including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America. He previously practiced clinical nephrology for more than two decades and has served http://www.streetinsider.com/Corporate+News/Humacyte+adds+two+nephrologists+as+advisors+for+dialysis+product+push/26765193.html Tue, 14 Jul 2026 08:04:46 -0400 HUMA http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Press+Releases/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Globe+Newswire/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Globe+Newswire/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241 http://www.streetinsider.com/Globe+Newswire/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html <p align="center"><em>- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -</em></p> <p align="center"><em>- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -</em></p> <p>DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at http://www.streetinsider.com/Globe+Newswire/Humacyte+Appoints+Key+Nephrologists+as+Advisors+to+Prepare+for+Planned+Commercialization+of+the+ATEV+in+Dialysis+Access/26765125.html Tue, 14 Jul 2026 08:00:00 -0400 A.06822034 A.22710740 A.23119014 A.27238098 A.30142833 A.31623535 A.35954321 A.37879753 A.50204560 A.50213484 HUMA O.00003102 O.00091935 O.00185691 O.20026344 O.20030242 O.20161007 O.20737027 O.22079093 O.22566009 O.29765439 O.39398241